Notes of Malaria *Libre* 1st project meeting
22nd July 2020; 1530-1630 (Indian Standard Time)

Participants: Sanjay Batra, Kishore Mohan, PP Yadav (CDRI, India); Shailja Singh (JNU, India); Shridhar Narayan (FNDR, India); Gloria Serra (Dept. of Chemistry, Uruguay), Martine Keenan (Epichem, Australia), Andrea Ruecker (MORU, Thailand), Jeremy Burrows (MMV, Switzerland), Kirandeep Samby (MMV, India)

**Discussion points:**

What is TCP for these compounds? It was explained that TCP will be clarified as the project progresses and more potent compounds are screened in various life stage assays.

What is the throughput of the primary assay and turn around and how many chemists are involved? It was highlighted that currently there are 2 chemists supporting the project at TCGLS and CDRI researchers are initiating synthesis of some of the compounds available in excel sheet on the webpages. TAT for 3D7 LDH assay is around 10 days if the compounds are available at TCGLS by Wednesday evening.

Would natural products be included in the scaffolds for further expansion? The focus is on small molecules. Right now, there are already two scaffolds and going ahead if these don’t fulfill the criteria of early lead, alternate scaffolds will be made available.

**Contributions:**

Shridhar: FNDR can profile compounds in *in vivo* PK studies

Andrea: Could do clinical isolate testing including artemisinin-resistance and DGFA in NF54 and resistant parasite isolates. She will confirm with lab head and get back

Martine: Will provide intellectual inputs and Epichem will contribute to compound synthesis when they can

Gloria: Can find alternates for replacement of imidazole; will come back with specific compounds after going through the available SAR

Sanjay/Kishore/PP: Chemistry is already initiated and CDRI will simultaneously perform primary screening in 3D7 and K1 strains of *P. falciparum* (assays available at CDRI)

Shailja: Will provide parasitology support as in generation of MoA, screening in clinical isolates of Pf.